November 21, 2024 Dear Speaker Johnson, Leader Jeffries, Leader Schumer, and Leader McConnell, As Congress returns to Washington for the remaining weeks of the legislative session, lawmakers have a critical opportunity to deliver meaningful reforms that will provide relief to millions of hardworking families struggling with high prescription drug costs. As a labor union representing […]
Recent News
Statement on the Bipartisan Infrastructure Act
Today, PILMA released the following statement applauding the passage of the Bipartisan Infrastructure Act November 6, 2021 Download the full statement here. PILMA commends Congress for passing landmark legislation that will put union men and women to work updating our nation’s infrastructure. This bill will put the safest, best trained, and highest-skilled workers on the […]
USTR Letter: WTO TRIPS
View letter from PILMA Executive Director, Tim Dickson October 22, 2021Katherine TaiUnited States Trade Representative600 17th Street, NWWashington, DC 20508 Dear Ambassador Tai, On behalf of the Pharmaceutical Industry Labor-Management Association (PILMA), which advances the dual goals of fostering innovation of life-saving cures and securing high-quality union construction jobs, I write to reiterate concerns we […]
Statement on WTO TRIPS Intellectual Property Waiver
On May 6, 2021, PILMA released the following statement on the far reaching negative impacts of the U.S. signing on to the WTO TRIPS waiver. Download the statement here. May 6, 2021 The U.S. Trade Representative’s decision to support waiving intellectual property protections for the COVID-19 vaccine is a danger to worldwide health and security, […]
USTR Letter: PILMA Supports Protection of Intellectual Property Rights
On March 1, 2021, General President of SMART and PILMA Chairman Joseph Sellers, Jr. sent the following letter to the Acting U.S. Trade Representative Maria L. Pagan urging continued protections of intellectual property: View letter from President Sellers. View letter from PILMA Executive Director Timothy Dickson. March 1, 2021Maria L. PaganActing United States Trade Representative600 […]
Data shows half of all spending on brand medicines is retained by manufacturer
Last year, PILMA in collaboration with union health care and benefits expert Randy DeFrehn released a report titled “An Understanding and Implications of the Cost Drivers in the Drug Supply Chain.” PILMA combined DeFrehn’s findings with data from a new report by Berkeley Research Group to extrapolate on the original report and provide insight into which entities in the supply chain are receiving an increasing share of revenue from prescription medicines.